Summary
This randomised, double-blind, phase 3 trial (RANGE) evaluated the efficacy and safety of ramucirumab, a vascular endothelial growth factor receptor 2 inhibitor, combined with docetaxel in patients with locally advanced or metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy. The trial enrolled participants across multiple countries and assessed overall survival as the primary endpoint, with updated results reported in 2019. As suggested by the trial design, the study aimed to determine whether anti-angiogenic therapy could improve outcomes in this platinum-refractory patient population.
UK applicability
The findings are directly applicable to UK oncology practice, as the trial enrolled patients from multiple European centres including the United Kingdom, and results would inform National Institute for Health and Care Excellence (NICE) appraisal and NHS treatment protocols for advanced urothelial carcinoma.
Key measures
Overall survival, progression-free survival, adverse events, response rates
Outcomes reported
The study assessed overall survival and safety outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with ramucirumab plus docetaxel versus placebo plus docetaxel following platinum-based therapy failure.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.